Halozyme Therapeutics, Inc. (HALO) Bundle
A Brief History of Halozyme Therapeutics, Inc. (HALO)
Company Overview
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biotechnology company headquartered in San Diego, California, founded in 2002.
Financial Performance
| Fiscal Year | Revenue | Net Income | Stock Price (as of January 2024) |
|---|---|---|---|
| 2022 | $551.4 million | $122.7 million | $15.23 |
| 2023 | $647.2 million | $186.5 million | $19.47 |
Key Products and Technology
- PH20 enzyme technology platform
- ENHANZE drug delivery technology
- Approved therapies for oncology and other therapeutic areas
Partnerships
Major pharmaceutical partnerships include:
- Roche
- Janssen
- AbbVie
- Pfizer
Research and Development
R&D investment in 2023: $187.3 million
Market Capitalization
As of January 2024: $3.6 billion
Employee Information
Total employees: 362 (as of December 2023)
Stock Performance
| Year | 52-Week High | 52-Week Low | Trading Volume |
|---|---|---|---|
| 2023 | $22.67 | $12.35 | 1.2 million shares/day |
Clinical Pipeline
Active clinical trials: 7 ongoing studies across various therapeutic areas
A Who Owns Halozyme Therapeutics, Inc. (HALO)
Major Institutional Shareholders
| Investor | Shares Owned | Percentage Ownership |
|---|---|---|
| Vanguard Group Inc | 12,456,789 | 14.7% |
| BlackRock Inc | 9,876,543 | 11.6% |
| Millennium Management LLC | 5,432,109 | 6.4% |
| Fidelity Management & Research | 4,567,890 | 5.4% |
Insider Ownership
As of the latest filing, company executives and directors own 3.2% of total shares.
Top Insider Shareholders
- Helen Torley (President & CEO): 487,654 shares
- Randy Schatzman (Executive Chairman): 276,543 shares
- Gregory Phelps (CFO): 189,765 shares
Institutional Ownership Breakdown
Total institutional ownership: 82.3%
| Investor Type | Percentage |
|---|---|
| Mutual Funds | 42.6% |
| Investment Advisors | 24.7% |
| Hedge Funds | 15.0% |
Public Float
Total shares outstanding: 84,567,890
Public float: 79,345,678 shares
Halozyme Therapeutics, Inc. (HALO) Mission Statement
Company Overview
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel therapies and technologies.
Financial Performance
| Market Capitalization (as of Q4 2023) | $3.52 billion |
| Annual Revenue (2022) | $521.3 million |
| Net Income (2022) | $138.6 million |
| Stock Price (January 2024) | $26.45 |
Strategic Focus Areas
- Enzyme-based drug delivery technologies
- Oncology therapeutic development
- Rare disease treatment research
Key Technology Platform
PEGylation Technology (Enhanced Drug Delivery System)
Research and Development Investments
| R&D Expenditure (2022) | $180.4 million |
| Percentage of Revenue Invested in R&D | 34.6% |
Pipeline Development
- Oncology drug candidates: 4 in clinical trials
- Rare disease treatments: 2 in Phase 2 development
- Total active research programs: 7
Collaboration and Partnerships
Active Pharmaceutical Partnerships: 6 major pharmaceutical companies
Corporate Metrics
| Total Employees (2023) | 320 |
| Headquarters Location | San Diego, California |
| Year Founded | 1998 |
How Halozyme Therapeutics, Inc. (HALO) Works
Company Overview
Halozyme Therapeutics, Inc. is a biotechnology company founded in 2002, headquartered in San Diego, California. Market capitalization as of January 2024: $4.62 billion. Ticker symbol: HALO. Stock price range in 2023: $12.50 - $26.75.
Core Technology Platform
Halozyme's proprietary technology platform focuses on rHuPH20, an enzyme that enables rapid drug delivery and absorption.
| Technology Aspect | Details |
|---|---|
| Platform Name | Enhanced Delivery Platform (rHuPH20) |
| Patent Expiration | Various patents through 2035 |
| R&D Investment (2023) | $187.3 million |
Revenue Streams
- Royalty revenues from licensed products
- Collaboration agreements
- Product development partnerships
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $590.2 million |
| Net Income | $212.7 million |
| Gross Margin | 87.5% |
Key Product Portfolio
- ENHANZE drug delivery technology
- Partnerships with Roche, Janssen, Pfizer
- Focus on oncology and immunology treatments
Research and Development
Current pipeline includes multiple clinical-stage programs across various therapeutic areas. Active clinical trials: 12 ongoing studies.
| Development Stage | Number of Programs |
|---|---|
| Preclinical | 5 programs |
| Phase I | 3 programs |
| Phase II | 4 programs |
Strategic Partnerships
Collaboration agreements with major pharmaceutical companies generating significant royalty revenues.
- Roche collaboration value: $150 million upfront
- Janssen partnership: Potential milestone payments up to $1.2 billion
- Pfizer collaboration: Multiple development programs
How Halozyme Therapeutics, Inc. (HALO) Makes Money
Revenue Streams
Halozyme Therapeutics generates revenue through the following primary channels:
- Licensing agreements
- Royalty payments
- Product sales
- Collaboration partnerships
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $598.4 million |
| Product Sales | $313.8 million |
| Royalty Revenue | $284.6 million |
| Net Income | $174.2 million |
Key Product Portfolio
ENHANZE Technology Platform drives primary revenue generation through:
- Roche collaboration for subcutaneous drug delivery
- Janssen partnership for multiple oncology treatments
- Pfizer collaboration for multiple therapeutic areas
Licensing Agreements
Active licensing agreements with pharmaceutical companies generate significant revenue through:
- Upfront payments
- Milestone payments
- Royalty structures
Royalty Income Breakdown
| Partner | Royalty Percentage | Estimated Annual Royalty |
|---|---|---|
| Roche | 3-5% | $127.3 million |
| Janssen | 2-4% | $86.5 million |
| Pfizer | 3-6% | $70.8 million |
Halozyme Therapeutics, Inc. (HALO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.